PolyTherics Receives Second Patent Allowance in Record Time
The patent claims the use of a unique linker developed at PolyTherics that enables precision attachment of PEG to natural disulfide bonds in proteins. Trademarked as TheraPEG™, the technology allows proteins with proven therapeutic efficacy such as Interferons, erythropoietin and antibody fragments to remain active and potent in the body for longer, resulting in less frequent dosing without loss of biological activity. TheraPEG™ has been shown to be a highly efficient, reliable and cost effective process which complements the proven cost benefits of bacterial expression to produce therapeutic proteins.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.